Filtern
Volltext vorhanden
- ja (2)
Gehört zur Bibliographie
- ja (2)
Dokumenttyp
- Dissertation (2)
Sprache
- Englisch (2) (entfernen)
Schlagworte
- Lipide (2) (entfernen)
Institut
- Graduate School of Life Sciences (2) (entfernen)
Whereas most currently used antibiotics act by interfering with essential bacterial processes, a smaller group of antibacterials disturbs the integrity of the cell membrane. Since fatty acids are a vital component of membrane phospholipids, the type-II fatty acid biosynthesis pathway (FAS-II) of bacteria constitutes a promising drug target. The front-line anti-tuberculosis prodrug isoniazid blocks the FAS-II pathway in M. tuberculosis thereby leading to morphological changes and finally to cell lysis. When it became evident that the enoyl-ACP reductase in the FAS-II pathway is the target of the activated isoniazid, several programs were initiated to develop novel inhibitors directed against this protein in different pathogens. The S. aureus enoyl-ACP reductase (saFabI) is of particular interest since three promising drug candidates inhibiting this homologue have reached clinical trials. However, despite these prospects, no crystal structures of saFabI were publicly available at the time the present work was initiated. Thus, one major goal of this thesis was the generation of high-resolution atomic models by means of X-ray crystallography. The development of a highly reproducible approach to co-crystallize saFabI in complex with NADP+ and diphenyl ether-based inhibitors led to crystal structures of 17 different ternary complexes. Additional crystallographic experiments permitted the view into two apo-structures and two atomic models of saFabI in complex with NADPH and 2-pyridone inhibitors. Based on the established saFabI structure, molecular dynamics (MD) simulations were performed to improve our understanding of the conformational mobility of this protein. Taken together, these investigations of the saFabI structure and its flexibility served as an ideal platform to address important questions surrounding substrate and inhibitor recognition by this enzyme. Intriguingly, our saFabI structures provide several vastly different snapshots along the reaction coordinate of ligand binding and hydride transfer, including the closure of the flexible substrate binding loop (SBL). The extraordinary mobility of saFabI was confirmed by MD simulations suggesting that conformational motions indeed play a pivotal role during substrate delivery and turnover. A water chain linking the active site with a water-basin inside the homo-tetrameric enzyme was found likely to be crucial for the closure and opening of the SBL and, thus, for the catalyzed reaction. Notably, the induced-fit ligand binding process involves a dimer-tetramer transition, which could be related to the observed positive cooperativity of cofactor and substrate binding. Overall, saFabI displays several unique characteristics compared to FabI proteins from other organisms that might be necessary for the synthesis of branched-chain fatty acids, which in turn are required for S. aureus fitness in vivo. This finding may explain why S. aureus is sensitive to FAS-II inhibitors even in the presence of exogenous fatty acids. Accordingly, saFabI remains a valid drug target and our structures can be used as a molecular basis for rational drug design efforts. In fact, binding affinity trends of diphenyl ether inhibitors and, more importantly, the correlated residence times could be rationalized at the molecular level. Furthermore, the structure of saFabI in complex with the 2-pyridone inhibitor CG400549 revealed unique interactions in the wider binding crevice of saFabI compared to other FabI homologues explaining the narrow activity spectrum of this clinical candidate with proven human efficacy. In summary, these studies provide an ideal platform for the development of new, effective saFabI inhibitors as exemplified by the promising 4-pyridone PT166. In the context of this dissertation, crystal structures of the condensing enzyme KasA in complex with several analogs of the naturally occurring inhibitor thiolactomycin have been solved.
The development of cellular life on earth is coupled to the formation of lipid-based biological membranes. Although many tools to analyze their biophysical properties already exist, their variety and number is still relatively small compared to the field of protein studies. One reason for this, is their small size and complex assembly into an asymmetric tightly packed lipid bilayer showing characteristics of a two-dimensional heterogenous fluid. Since membranes are capable to form dynamic, nanoscopic domains, enriched in sphingolipids and cholesterol, their detailed investigation is limited to techniques which access information below the diffraction limit of light. In this work, I aimed to extend, optimize and compare three different labeling approaches for sphingolipids and their subsequent analysis by the single-molecule localization microscopy (SMLM) technique direct stochastic optical reconstruction microscopy (dSTORM). First, I applied classical immunofluorescence by immunoglobulin G (IgG) antibody labeling to detect and quantify sphingolipid nanodomains in the plasma membrane of eukaryotic cells. I was able to identify and characterize ceramide-rich platforms (CRPs) with a size of ~ 75nm on the basal and apical membrane of different cell lines. Next, I used click-chemistry to characterize sphingolipid analogs in living and fixed cells. By using a combination of fluorescence microscopy and anisotropy experiments, I analyzed their accessibility and configuration in the plasma membrane, respectively. Azide-modified, short fatty acid side chains, were accessible to membrane impermeable dyes and localized outside the hydrophobic membrane core. In contrast, azide moieties at the end of longer fatty acid side chains were less accessible and conjugated dyes localized deeper within the plasma membrane. By introducing photo-crosslinkable diazirine groups or chemically addressable amine groups, I developed methods to improve their immobilization required for dSTORM. Finally, I harnessed the specific binding characteristics of non-toxic shiga toxin B subunits (STxBs) and cholera toxin B subunits (CTxBs) to label and quantify glycosphingolipid nanodomains in the context of Neisseria meningitidis infection. Under pyhsiological conditions, these glycosphingolipids were distributed homogenously in the plasma membrane but upon bacterial infection CTxB detectable gangliosides accumulated around invasive Neisseria meningitidis. I was able to highlight the importance of cell cycle dependent glycosphingolipid expression for the invasion process. Blocking membrane accessible sugar headgroups by pretreatment with CTxB significantly reduced the number of invasive bacteria which confirmed the importance of gangliosides for bacterial uptake into cells. Based on my results, it can be concluded that labeling of sphingolipids should be carefully optimized depending on the research question and applied microscopy technique. In particular, I was able to develop new tools and protocols which enable the characterization of sphingolipid nanodomains by dSTORM for all three labeling approaches.